Showing results (51-60 of 369) with videos related to

Sort By:
Pageof 37
Clinical Nuclear Medicine|November 4, 2017
Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CTFrancois H Cornelis, Jeremy C Durack, Michael J Morris, et al.
European Urology|October 26, 2019
Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate CancerRyon P Graf, Melanie Hullings, Ethan S Barnett, et al.
Cancer|September 21, 2016
Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trialYohann Loriot, Karim Fizazi, Johann S de Bono, et al.
Molecular Carcinogenesis|September 25, 2004
Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular eventsF M Sirotnak, Yuhong She, Nushmia Z Khokhar, et al.
Seminars in Oncology|October 23, 2003
DNA vaccines: an active immunization strategy for prostate cancerJedd D Wolchok, Polly D Gregor, Luke T Nordquist, et al.
Nature Reviews. Clinical Oncology|October 18, 2017
Drug development for noncastrate prostate cancer in a changed therapeutic landscapeMin Yuen Teo, Matthew J O'Shaughnessy, Sean M McBride, et al.
Nature Reviews. Clinical Oncology|November 9, 2017
Drug development for noncastrate prostate cancer in a changed therapeutic landscapeMin Yuen Teo, Matthew J O'Shaughnessy, Sean M McBride, et al.
Investigational New Drugs|September 14, 2020
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancerBenjamin A Gartrell, Mack Roach, Avi Retter, et al.
Expert Review of Clinical Pharmacology|November 25, 2011
Finding the place of histone deacetylase inhibitors in prostate cancer therapyDeborah L Marrocco-Tallarigo, Margaret M Centenera, Howard I Scher, et al.
Urology|February 1, 2003
Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trialDavid Andrew Verbel, W Kevin Kelly, Oren Smaletz, et al.
Pageof 37